To determine whether NKG2D-CD3 and NKG2D-CD16 could stimulate effector cells of pretreated STS patients in a similar manner as in healthy donors, we employed an experimental setting independent of target cell binding. The gene discussed is KLRK1; the disease is telomere syndrome.